Bioinformatics Data Analyst in Cancer Immunology , Research Institute of Molecular Pathology

The Research Institute of Molecular Pathology (IMP) in Vienna is recruiting a bioinformatics data analyst for a collaborative research project focused on the discovery and pre-clinical analysis of candidate therapeutic targets for cancer immunotherapy. Strategies aimed at re-arming tumor-specific T cells through checkpoint blockade have recently led to major break¬throughs in the treatment of aggressive cancers such as melanoma and lung cancer. To identify and study new targets for immunomodulatory therapy, the Zuber and Busslinger labs at IMP, in close collaboration with the Carotta lab at Boehringer Ingelheim RCV, are pursuing an integrative approach combining innovative cancer models, genome/epigenome profiling and functional genetic studies. We are looking for a highly motivated and experienced bioinformatics data analyst that will lead the integration of transcriptomic, genomic, epigenetic and functional screening data.
As bioinformatics data analyst in our team you will:
1.    work at the IMP, one of Europe’s leading research institutes providing a top-notch infrastructure and excellent financial support through institutional and public funding (e.g. currently 8 ERC grants).
2.    be fully embedded in a group of experienced computational biologists / bioinformaticians affiliated with different research groups at the IMP, ensuring constant interactions, support and training.
3.    become an integral member of our cancer immunotherapy team with deep intellectual project involvement and close interactions with wet lab scientists and supervising PIs.
4.    be in charge of integrating and interpreting comprehensive next generation sequencing datasets (RNA-Seq, ChIP-Seq, GRO-seq, Hi-C) generated by our team with support from our state-of-the-art NGS facility (http://www.vbcf.ac.at/facilities/next-generation-sequencing/).
5.    be involved in method development of novel NGS applications (e.g. STARR-seq, single-cell RNA-seq, CRISPR/Cas9 screening analysis) and lead the establishment of related analysis tools and workflows.
6.    interact with other computational biologists at IMP and Boehringer Ingelheim and receive support for out-of-the box projects, specialized training and scientific conferences.
Successful candidates should:
1.    hold an academic degree / PhD in Bioinformatics, Biostatistics or Life Sciences
2.    have several years of experience in NGS data analysis, including profound knowledge in scripting/ programming and common standard tools and algorithms.
3.    have a sound knowledge of machine learning and statistical methods, as well as fluent programming skills in R/Bioconductor and at least one more scripting language.
4.    be proficient with UNIX-like operating systems (experience with relational databases is a strong plus).
5.    have excellent communication skills in English, an ability to translate and communicate results, and a basic understanding of cancer biology and immunology.
The salary is commensurate with qualifications/experience and includes a comprehensive benefits package. Applications, including a letter of motivation describing your particular interest in this position and past research experiences, a CV and the names and contact details of referees should be sent to zuber@imp.ac.at. The application deadline is March 12, 2016.
        Further information:    http://www.imp.ac.at/research/research-groups/zuber-group/
http://www.imp.ac.at/research/research-groups/busslinger-group/
http://www.vbcf.ac.at/facilities/next-generation-sequencing/
http://www.boehringer-ingelheim.at/f_e_r_d/english_version.html